Compare Capri Holdings Ltd (CPRI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | XBI | |
|---|---|---|
Market Cap | $1.75B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $27.66 | $164.28 |
52-Week Low | $14.98 | $86.92 |
Enterprise Value | $3.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.66, down 65% over five years and near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with neutral oscillators but faces fundamental challenges including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a net loss of $1.18B last year. Recent Q1 2027 earnings beat expectations with $0.67 EPS versus $0.41 expected, driven by margin improvements and Jimmy Choo growth, though management cut full-year revenue guidance citing Michael Kors weakness.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with the stock trading below consensus price targets offering potential upside if Michael Kors stabilizes. However, significant risks remain including ongoing revenue declines, luxury market softness, and high debt levels requiring careful monitoring of quarterly execution against revised guidance.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
